Safety and Efficacy of Diverse Mesenchymal Stem Cells Transplantation for Liver Failure
Status:
Unknown status
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
HBV-related liver failure (HBV-LF), a dramatic clinical syndrome, is characterized with
massive necrosis of liver cells. Liver transplantation might be the most effective therapy
for HBV-LF. However, there are a lot of problems such as lack of donors, surgical
complications, transplant rejection, and high cost, which could limit the application of
liver transplantation. It is demonstrated that mesenchymal stem cells could directionally
differentiate into hepatocytes and cholangiocytes in injured liver, as well as reduce
inflammation of the liver by immune regulation. In this study, we assess the safety and
efficacy of human bone marrow and umbilical cord mesenchymal stem cells transplantation for
patients with HBV-LF.